Insider Buying: NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Purchases $12,775.86 in Stock

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) major shareholder Poplar Point Capital Partners bought 21,654 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The stock was purchased at an average price of $0.59 per share, with a total value of $12,775.86. Following the transaction, the insider now directly owns 971,654 shares in the company, valued at $573,275.86. The trade was a 2.28 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

• On Friday, January 31st, Poplar Point Capital Partners purchased 70,685 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.65 per share, for a total transaction of $45,945.25.
• On Monday, January 27th, Poplar Point Capital Partners acquired 31,703 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.69 per share, with a total value of $21,875.07.
• On Thursday, February 20th, Poplar Point Capital Partners bought 1,836 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average price of $0.63 per share, for a total transaction of $1,156.68.
• On Tuesday, February 18th, Poplar Point Capital Partners purchased 3,222 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average price of $0.66 per share, with a total value of $2,126.52.
• On Monday, February 3rd, Poplar Point Capital Partners acquired 2,597 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average price of $0.64 per share, for a total transaction of $1,662.08.
• On Friday, March 7th, Poplar Point Capital Partners bought 102 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average price of $0.55 per share, with a total value of $56.10.
• On Tuesday, March 4th, Poplar Point Capital Partners purchased 4,000 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.58 per share, for a total transaction of $2,320.00.
• On Thursday, February 27th, Poplar Point Capital Partners acquired 385 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.61 per share, with a total value of $234.85.
• On Tuesday, February 25th, Poplar Point Capital Partners purchased 25,033 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average price of $0.62 per share, with a total value of $15,520.46.
• On Friday, March 14th, Poplar Point Capital Partners purchased 25,511 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.63 per share, for a total transaction of $16,071.93.

NovaBay Pharmaceuticals Stock Performance

Shares of NBY stock opened at $0.60 on Friday. The firm has a market cap of $3.49 million, a P/E ratio of -0.01 and a beta of 0.90. The business’s 50 day moving average price is $0.60 and its 200-day moving average price is $0.63. NovaBay Pharmaceuticals, Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $9.08.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of NovaBay Pharmaceuticals in a report on Friday. They set a “hold” rating for the company.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.